B · Normal
[Hualan Biological: Its controlled subsidiary has been approved for clinical trials of the new influenza virus mRNA vaccine] On September 7, Hualan Biological (002007.SZ) announced that the company's controlled subsidiary Hualan Biological Vaccine received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, agreeing to conduct clinical trials of the new influenza virus mRNA vaccine to prevent influenza. This vaccine is the first influenza virus mRNA vaccine in China to obtain implicit permission for clinical trials. Its research and development has entered the clinical trial stage, and there are still uncertainties in the follow-up.
Comments